Webinars and Sponsored Roundtables — Register Now

Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.

Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Subspecialties

Unsatisfactory Paps—recommendations, remedies

May 2026—The Papanicolaou test has been a model for cancer screening and prevention since its introduction well over half a century ago. Despite the evolution and innovations in HPV vaccination, testing methodologies, reporting systems, and treatment algorithms, cervicovaginal and lower genital tract cytology continues to be a workhorse for providers and laboratories.

AI in cytology: where digital meets diagnostic

May 2026—Digital pathology has evolved substantially over the past decade. What started primarily as a platform for image storage now supports educational initiatives, remote signout, consultation, and image analysis deployment.

Complimentary online CME/CE activity for NGC program enrollees

May 2026—Education is one of the CAP’s core missions, closely linked to its commitment to advocacy and excellence in practice. In addition to its overarching laboratory improvement programs, the CAP provides educational offerings in a variety of formats, designed to satisfy the learning needs of its members and of a diverse group of laboratory professionals.

In brain tumors, new use for CSF cfDNA

April 2026—It’s hard to mount an argument against the Great Plains. Nor is there much reason to. But drive across eastern Colorado, Nebraska, Kansas, or the Dakotas, and it is a bona fide thrill to arrive in Wyoming’s northwest corner and see the Grand Tetons rising up in spectacular fashion.

ASCO to shine light on multimodal AI models:
Plus, melanoma diagnostics and gastroesophageal cancer targets

April 2026—Artificial intelligence, circulating tumor DNA, trial data: ASCO 2026 next month in Chicago will feature platforms, technologies, and therapeutic approaches once considered future concepts in cancer diagnosis and care. What comes now is less flashy than a breakthrough advance perhaps, but no less significant. As Janice Lu, MD, PhD, puts it, “The real work now is disciplined clinical translation: validation, collaboration, and implementation, in ways that truly improve patient care.”

New susceptibility subsection with a broad scope

April 2026—A new general susceptibility subsection in the microbiology checklist consolidates requirements for antibacterials, antifungals, and antimycobacterials, aiming for clarity and a broader focus beyond bacteriology.

Alzheimer’s blood tests poised to lead

March 2026—For a pathology that is invariably associated with dimming—of memory, of relationships, of personality—Alz-heimer’s disease has been linked to remarkably bright news as of late. Blood-based biomarkers, including two that garnered FDA approval last year, have cracked open the door to earlier diagnoses and therapeutic interventions, as well as the potential to reach more patients.

In MS diagnosis, the case for κ-FLC index

March 2026—An international panel of experts in multiple sclerosis and cerebrospinal fluid diagnostics reached a consensus in 2023, and they recommended including the determination of intrathecal kappa free light chain synthesis in the next revision of MS diagnostic criteria as an additional tool to measure intrathecal immunoglobulin synthesis.